Xenetic Biosciences
XBIO
7 hedge funds and large institutions have $736K invested in Xenetic Biosciences in 2019 Q2 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.72% more ownership
Funds ownership: 0.04% → 0.75% (+0.72%)
8% less capital invested
Capital invested by funds: $797K → $736K (-$61.3K)
22% less funds holding
Funds holding: 9 → 7 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$474K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$22.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$90K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$35K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$13.5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $406K | +$474K | +3,582 | +13,777% |
|
2
Royal Bank of Canada
Toronto,
Ontario, Canada
| $304K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $21K | +$22.9K | +173 | +1,442% |
|
|
PAM
4
Panagora Asset Management
Boston,
Massachusetts
| $4K | -$13.5K | -102 | -75% |
|
|
RE
5
RBC Europe
London,
United Kingdom
| $1.18K | – | – | – |
|
|
6
Vanguard Group
Malvern,
Pennsylvania
| – | -$90K | -388 | Closed |
|
|
7
Acadian Asset Management
Boston,
Massachusetts
| – | -$35K | -151 | Closed |
|
XBIO Hedge Fund Activity: Q2 2019 in Review
7 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q2 2019, worth a combined $736K — down 7.7% from $797K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of XBIO and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was Morgan Stanley, adding an estimated $474K. The largest seller was Vanguard Group, exiting entirely with an estimated $90K sold.
- 7 institutional investors held Xenetic Biosciences (XBIO) as of Q2 2019, down from 9 in Q1 2019.
- Funds reported $736K of Xenetic Biosciences stock for Q2 2019, down 7.7% quarter-over-quarter.
- 0 funds opened new Xenetic Biosciences positions in Q2 2019 and 2 closed out, a net change of -2 holders.
- The largest Xenetic Biosciences buyer in Q2 2019 was Morgan Stanley, an estimated $474K added.
- The largest Xenetic Biosciences seller in Q2 2019 was Vanguard Group, an estimated $90K sold.
Based on aggregated 13F filings for Q2 2019.